NewAmsterdam Pharma Company N.V
NAMS
Positions held
Your positionsNAMS isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- NewAmsterdam Pharma operates in the biotechnology sector, which is characterized by rapid innovation and potential for significant breakthroughs in healthcare.
- Revenue increased by 22% compared to the prior quarter, reaching $3.7 million.
- The company has a strong current ratio of 9.033, indicating good short-term financial health.
- The biotechnology industry is highly competitive, with many companies vying for market share and funding, which can pressure smaller firms like NewAmsterdam Pharma.
- The operating margin remains severely negative at -1752.6%, reflecting ongoing financial challenges.
- NewAmsterdam Pharma's revenue growth has been declining, with a total revenue of only $14.09 million in 2023, down from $45.563 million in 2024.
Fundamentals
| Market cap | $2.49B | Enterprise value | $1.91B | Trailing P/E | — | Forward P/E | -13.92 |
| PEG | — | Price / book | 3.96 | Beta | 0.10 | Dividend yield | 0.00% |
| Revenue growth | -80.7% | Earnings growth | — | Gross margin | 100.0% | Operating margin | -17.5% |
| Profit margin | 0.0% | ROE | -36.8% | ROA | -20.1% | Debt / equity | 0.00 |
| Current ratio | 9.03 | Free cash flow | -$45.36M | Analyst recommendation | strong_buy | Mean target | $49.77 |
| 52w high | $42.21 | 52w low | $20.91 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $3.7M | $3.0M | $0.0M | $0.3M | $19.1M | — |
| Op margin | -1752.6% | -1921.7% | -206187.5% | -15845.7% | -186.1% | — |
| Net income | -$64.1M | -$48.4M | -$74.9M | -$72.0M | -$17.4M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$64.9M | -$58.4M | -$66.0M | -$55.1M | -$35.6M | — |
- Revenue +22% vs prior quarter ($3.7M vs $3.0M).
- Operating margin expanded to -1752.6%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $22.5M | $45.6M | $14.1M | $103M | — |
| Op margin | -1002.9% | -386.9% | -1298.6% | -3.5% | — |
| Net income | -$204M | -$242M | -$177M | -$22.6M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$226M | -$176M | -$183M | -$3.6M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-05 · NewAmsterdam PREVAIL Interim Faces 'Considerable' Risk, RBC Says
2026-10-05 · RBC Cuts Price Target on NewAmsterdam Pharma to $42 From $50, Keeps Outperform, Speculative Risk
2026-10-02 · Group 1 Automotive and 4 More Stocks See Action From Activist Investors
2026-10-02 · NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-29 · NewAmsterdam Pharma Doses First Participant in Phase 2b Trial for Preclinical Alzheimer's Disease
2026-09-23 · NewAmsterdam Pharma (NAMS) Wins EU Approvals. Can Cholesterol Pills Drive Royalties?
2026-09-21 · NewAmsterdam Pharma Gets EU Approval for Ubeslo, Evlarco
2026-09-20 · NewAmsterdam Pharma (NAMS) Stock Looks Above Fair Value After Its 139% Run
2026-09-15 · Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock?
2026-09-08 · How Novartis' Double-Stacked Failures Reverberated Through Biopharma
Price (daily)
Full chart · RSI · MACD · patterns